1. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer
   Fatemeh Saghafi et al, 2024, Journal of Pharmaceutical and Biomedical Analysis CrossRef
2. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
   Carmen W. H. Chan et al, 2020, Journal of Cancer Research and Clinical Oncology CrossRef
3. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data
   Bianca Kruger et al, 2024, Clinical and Translational Science CrossRef
4. Pharmacogenomics research and clinical implementation in Brazil
   Fernanda Rodrigues‐Soares et al, 2019, Basic & Clinical Pharmacology & Toxicology CrossRef
5. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
   Lucas Soares Bezerra et al, 2018, Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics CrossRef
6. Pharmacogenetic testing in oncology: a Brazilian perspective
   Guilherme Suarez-Kurtz, 2018, Clinics CrossRef
7. CYP2D6 does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment
   Jorge-Aarón Rangel-Méndez et al, 2020, Personalized Medicine CrossRef
8. Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics
   Ondřej Slanař et al, 2021, Expert Opinion on Drug Metabolism & Toxicology CrossRef
9. Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics
   Deirdre P. Cronin-Fenton et al, 2018, Pharmacogenetics CrossRef
10. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen
    Fatemeh Saghafi et al, 2018, Biomedical Reports CrossRef